2025 ASCO Annual Meeting will be held May 30th-June 3rd. Below are links to abstracts being presented during the meeting.
- Time-weighted ctDNA dynamics for precision monitoring of relapse risk in colon cancer.
- Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.
- Minimal residual disease (MRD) test utilization in the first 6 months after initiating MRD testing in patients with colorectal cancer (CRC).
- ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer.
- The association of ctDNA with recurrence in patients with stage II-IV colorectal cancer: The ꞵ-CORRECT study.
- Signatera ctDNA in stage II CRC: A retrospective comparison with traditional risk factors for survival and prognostic stratification.
- Postoperative cfDNA levels and ctDNA detection rates in patients with stage II colon cancer screened for CIRCULATE (AIO-KRK-0217, ABCSG).
- Impact of perioperative complications on ctDNA-based MRD detection and prognosis: Insights from the GALAXY study.
- Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study.
- Association between ctDNA levels, timing of blood collection, and overall survival in metastatic colorectal cancer.
- Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): The REMARRY & PURSUIT trials.
- A phase Ib study of immunotherapy with ex-vivo pre-activated and expanded CBNK cells in combination with cetuximab, in patients with colorectal cancer (CRC) with minimal residual disease (MRD): Final report.
- Use of molecular residual disease (MRD) testing with measurement of circulating tumor DNA (ctDNA) post-operatively in stage II colon cancer (SIICC) in the community-based setting.
